Maxim Group Initiates Coverage On Telomir Pharmaceuticals with Buy Rating, Announces Price Target of $4
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Maxim Group analyst Jason McCarthy initiates coverage on Telomir Pharmaceuticals (NASDAQ:TELO) with a Buy rating and announces Price Target of $4.
Maxim Group analyst Jason McCarthy initiates coverage on Telomir Pharmaceuticals (NASDAQ:TELO) with a Buy rating and announces Price Target of $4.